It's no secret that the preclinical phase of drug development is costly and time consuming one. Outsourcing this phase of the drug development cycle can help minimize costs, meet deadlines, and fulfill the market need. Physiogenix has been able to help dozens of organizations successfully develop and progress compounds through their pipelines.  We specialized in preclinical services for diabetes, metabolic, cardiovascular, and other chronic illnesses. We work to develop long term relationships with our clients, based on trust and communication. We have worked with 8 of the top 20 pharmaceutical companies, many of which have worked with Physiogenix on multiple studies. 

We pride ourselves on working closely with our clients to develop customized research programs in the fields of diabetes, metabolic syndrome, cardiovascular disease, and neurology. As a preclinical CRO, we use several of our proprietary research models to mimic disease progression seen in humans to more accurately translate preclinical results into clinical ones. The data we collect from your studies is delivered on a real-time basis, allowing for agile study re-composition when necessary.